Summit Therapeutics SMMT Preferred Stock, Par or Stated Value Per Share
Preferred Stock, Par or Stated Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's preferred stock, par or stated value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's preferred stock, par or stated value per share?
- Summit Therapeutics (SMMT) reported preferred stock, par or stated value per share of $0.01 in Q1 2026.
- How has Summit Therapeutics's preferred stock, par or stated value per share changed year-over-year?
- Summit Therapeutics's preferred stock, par or stated value per share decreased by 0.0% year-over-year, from $0.01 to $0.01.
- What is the long-term trend for Summit Therapeutics's preferred stock, par or stated value per share?
- Over 4 years (2021 to 2025), Summit Therapeutics's preferred stock, par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.01 to $0.01.